Kezar Life Sciences, Inc. Common Stock
KZR US49372L1008
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Schiller Mark C. COO |
4.28 USD |
561 Sold |
2,401 USD |
02/07/2025 | 02/07/2025 |
Chiang Pichi Luo VP |
4.28 USD |
264 Sold |
1,130 USD |
02/07/2025 | 02/07/2025 |
Schiller Mark C. CLO |
0.58 USD |
6,688 Sold |
3,879 USD |
02/07/2024 | 02/07/2024 |